Preclinical and Clinical Development of Deferitrin, a Novel, Orally Available Iron Chelator
| Autor: | Judith K. Marquis, Melissa Plone, Joanne M. Donovan, Rafif Dagher, Mark Bree |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Iron Overload
Iron Carboxylic Acids Drug Evaluation Preclinical Administration Oral Pharmacology Iron Chelating Agents General Biochemistry Genetics and Molecular Biology Feces Dogs History and Philosophy of Science medicine Animals Humans Chelation therapy Iron Chelator Clinical Trials Phase I as Topic Molecular Structure business.industry General Neuroscience beta-Thalassemia Preclinical pharmacology Beta thalassemia Deferitrin medicine.disease Chelation Therapy Rats Macaca fascicularis Thiazoles business |
| Zdroj: | Annals of the New York Academy of Sciences. 1054:492-494 |
| ISSN: | 1749-6632 0077-8923 |
| DOI: | 10.1196/annals.1345.071 |
| Popis: | Deferitrin, a novel, orally available iron chelator, is in the early stage of clinical development for the treatment of chronic iron overload due to transfusional therapy. Preclinical pharmacology studies demonstrate iron excretion largely by the fecal route. Initial clinical studies have shown deferitrin to be well absorbed. Further clinical studies are ongoing to determine the efficiency and safety of deferitrin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text